HC Wainwright reaffirmed their buy rating on shares of Redhill Biopharma (NASDAQ:RDHL) in a report released on Tuesday, November 21st. They currently have a $36.00 price target on the biotechnology company’s stock.
RDHL has been the subject of a number of other research reports. Zacks Investment Research upgraded Redhill Biopharma from a sell rating to a hold rating in a report on Tuesday, August 29th. UBS started coverage on Redhill Biopharma in a research report on Wednesday, September 13th. They issued a reduce rating on the stock. Roth Capital cut their target price on Redhill Biopharma from $27.00 to $20.00 and set a buy rating on the stock in a research report on Tuesday, November 14th. Finally, Seaport Global Securities started coverage on Redhill Biopharma in a research report on Friday, October 6th. They issued a buy rating and a $19.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $21.10.
Shares of Redhill Biopharma (RDHL) traded up $0.35 during trading hours on Tuesday, hitting $4.95. The company’s stock had a trading volume of 240,159 shares, compared to its average volume of 97,728. Redhill Biopharma has a fifty-two week low of $4.30 and a fifty-two week high of $11.99.
Several hedge funds have recently bought and sold shares of RDHL. Bank of New York Mellon Corp purchased a new stake in shares of Redhill Biopharma during the 1st quarter worth about $101,000. Renaissance Technologies LLC boosted its stake in shares of Redhill Biopharma by 144.1% during the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after acquiring an additional 36,600 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in shares of Redhill Biopharma by 10.8% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock worth $220,000 after acquiring an additional 2,500 shares in the last quarter. D.A. Davidson & CO. boosted its stake in shares of Redhill Biopharma by 10.0% during the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Family Management Corp lifted its stake in Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock valued at $222,000 after buying an additional 8,750 shares in the last quarter. 8.47% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Redhill Biopharma’s (NASDAQ:RDHL) Buy Rating Reiterated at HC Wainwright” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/07/redhill-biopharma-ltd-rdhl-given-buy-rating-at-hc-wainwright.html.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.